Skip to main content
OpenTrials
Completed

NCT Number: NCT02175264

Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia

In isolated congenital diaphragmatic hernia (CDH), recurrent risk is low suggesting the occurrence of novo mutations (dominant or recessive). Our objective is to test this hypothesis by combining the search for pathogenic genomic alteration and intragenic mutations through whole exome sequencing in a homogenous group of patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 month and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hopital béclère

Clamart, 92141, France

About this study

To elucidate the genetic basis of non syndromic congenital diaphragmatic hernia in a sub group of individuals with similar phenotype: Isolated CDH presenting with postero-lateral-left diaphragmatic defect with good perinatal outcome (n=16) To establish the prevalence of the identified gene(s) in a cohort of identical patients (n=30)

Two complementary approaches will be used:

  • Search for pathogenic genomic alterations using microarrays (~2.106 markers (SNP and CNV) in 16 trios (affected child and 2 parents).
  • Sequencing of the whole exome from patient genomic DNA (n=16)
  • Selection of unknown or very rare variants according to different criteria: recessive or dominant model, prediction of their pathogenicity, filtered on genes already known in CDH or involved in diaphragmatic development and non annotated CNV or variants of new gene(s) shared by different patients.
  • Variants will be validated by Sanger sequencing (for intragenic variants) or quantitative PCR (for CNV) on CDH cases and their parents as well as their absence on 100 controls.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Families with one (or more) non syndromic CDH child
  • Signed consent form

Exclusion criteria

  • Syndromic CDH or associated with a known karyotype anomaly
  • No signed consent form
  • Not affiliated to French social security

Treatment and study plan

blood sample

Genetic

Primary outcomes

  1. genes responsible for isolated CDH

    Time frame: One year

Secondary outcomes

  1. prevalence of new identified genes in a cohort of CDH

    Time frame: One year

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Acronym: HCD GENE

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Jun 26, 2014
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.